Overview

  • Product nameAnti-PTEN antibody
    See all PTEN primary antibodies
  • Description
    Sheep polyclonal to PTEN
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Fusion protein, corresponding to amino acids 188-403 of Human PTEN.

Properties

Applications

Our Abpromise guarantee covers the use of ab16125 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use at an assay dependent dilution. Predicted molecular weight: 47 kDa.

Target

  • FunctionTumor suppressor. Acts as a dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Also acts as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring from phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3,4-diphosphate, phosphatidylinositol 3-phosphate and inositol 1,3,4,5-tetrakisphosphate with order of substrate preference in vitro PtdIns(3,4,5)P3 > PtdIns(3,4)P2 > PtdIns3P > Ins(1,3,4,5)P4. The lipid phosphatase activity is critical for its tumor suppressor function. Antagonizes the PI3K-AKT/PKB signaling pathway by dephosphorylating phosphoinositides and thereby modulating cell cycle progression and cell survival. The unphosphorylated form cooperates with AIP1 to suppress AKT1 activation. Dephosphorylates tyrosine-phosphorylated focal adhesion kinase and inhibits cell migration and integrin-mediated cell spreading and focal adhesion formation. Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue. The nuclear monoubiquitinated form possesses greater apoptotic potential, whereas the cytoplasmic nonubiquitinated form induces less tumor suppressive ability. In motile cells, suppresses the formation of lateral pseudopods and thereby promotes cell polarization and directed movement.
    Isoform alpha: Functional kinase, like isoform 1 it antagonizes the PI3K-AKT/PKB signaling pathway. Plays a role in mitochondrial energetic metabolism by promoting COX activity and ATP production, via collaboration with isoform 1 in increasing protein levels of PINK1.
  • Tissue specificityExpressed at a relatively high level in all adult tissues, including heart, brain, placenta, lung, liver, muscle, kidney and pancreas.
  • Involvement in diseaseCowden syndrome 1
    Lhermitte-Duclos disease
    Bannayan-Riley-Ruvalcaba syndrome
    Squamous cell carcinoma of the head and neck
    Endometrial cancer
    PTEN mutations are found in a subset of patients with Proteus syndrome, a genetically heterogeneous condition. The molecular diagnosis of PTEN mutation positive cases classifies Proteus syndrome patients as part of the PTEN hamartoma syndrome spectrum. As such, patients surviving the early years of Proteus syndrome are likely at a greater risk of developing malignancies.
    Glioma 2
    VACTERL association with hydrocephalus
    Prostate cancer
    Macrocephaly/autism syndrome
    A microdeletion of chromosome 10q23 involving BMPR1A and PTEN is a cause of chromosome 10q23 deletion syndrome, which shows overlapping features of the following three disorders: Bannayan-Zonana syndrome, Cowden disease and juvenile polyposis syndrome.
  • Sequence similaritiesContains 1 C2 tensin-type domain.
    Contains 1 phosphatase tensin-type domain.
  • DomainThe C2 domain binds phospholipid membranes in vitro in a Ca(2+)-independent manner; this binding is important for its tumor suppressor function.
  • Post-translational
    modifications
    Constitutively phosphorylated by CK2 under normal conditions. Phosphorylated in vitro by MAST1, MAST2, MAST3 and STK11. Phosphorylation results in an inhibited activity towards PIP3. Phosphorylation can both inhibit or promote PDZ-binding. Phosphorylation at Tyr-336 by FRK/PTK5 protects this protein from ubiquitin-mediated degradation probably by inhibiting its binding to NEDD4. Phosphorylation by ROCK1 is essential for its stability and activity. Phosphorylation by PLK3 promotes its stability and prevents its degradation by the proteasome.
    Monoubiquitinated; monoubiquitination is increased in presence of retinoic acid. Deubiquitinated by USP7; leading to its nuclear exclusion. Monoubiquitination of one of either Lys-13 and Lys-289 amino acid is sufficient to modulate PTEN compartmentalization. Ubiquitinated by XIAP/BIRC4.
  • Cellular localizationSecreted. May be secreted via a classical signal peptide and reenter into cells with the help of a poly-Arg motif and Cytoplasm. Nucleus. Nucleus, PML body. Monoubiquitinated form is nuclear. Nonubiquitinated form is cytoplasmic. Colocalized with PML and USP7 in PML nuclear bodies. XIAP/BIRC4 promotes its nuclear localization.
  • Information by UniProt
  • Database links
  • Alternative names
    • 10q23del antibody
    • BZS antibody
    • DEC antibody
    • GLM2 antibody
    • MGC11227 antibody
    • MHAM antibody
    • MMAC1 antibody
    • MMAC1 phosphatase and tensin homolog deleted on chromosome 10 antibody
    • Mutated in multiple advanced cancers 1 antibody
    • Phosphatase and tensin homolog antibody
    • Phosphatase and tensin like protein antibody
    • Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN antibody
    • Pten antibody
    • PTEN_HUMAN antibody
    • PTEN1 antibody
    • TEP1 antibody
    see all

Anti-PTEN antibody images



  • Predicted band size : 47 kDa


    ab16125 used at 20ug/ml in Western blot analysis of PTEN in various cell lines: Lane 1: ANA3CA (truncating mutations of PTEN). Lane 2: Hec 1A (wild-type PTEN). Lane 3: KLE (wild-type PTEN). Lane 4: MDA ((truncating mutations of PTEN). Lane 5: RL-95 (truncating mutations of PTEN). Lane 6: 293T (wild-type PTEN, low levels). Lane 7: 292T cells transfected with FLAG PTEN. Lane 8: Negative control.

References for Anti-PTEN antibody (ab16125)

ab16125 has not yet been referenced specifically in any publications.

Product Wall

Unfortunately, we do not have any more specific information regarding the Western blot image shown on the datasheet. This product was produced in collaboration with a researcher who did the testing for us and they did not provide any more information t...

Read More

Thank you for your recent phone call regarding our PTEN antibodies. After n extensive search on each datasheet I was unfortunately unable to find an antibody which would match your needs, I am still waiting to hear more information regarding ab13590....

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"